Table 5 Radiotherapy for locally advanced salivary gland carcinomas
First Author, Year | Cancer type | No. of patients | Treatment | LC rates (5-, 10-year) | PFS rates 5-year | OS rates 5-, 10-year |
|---|---|---|---|---|---|---|
Mendenhall, 2004 [36] | T4 ACC | 42 | Radiotherapy | 44%, 30% | / | 50%, 29% |
Chen, 2006 [37] | T4 salivary gland carcinomas | 12 | Radiotherapy | 42%, 30% | / | 42%, 37% |
Douglas, 2000 [38] | Locally advanced ACC | 151 | fast Neutron radiotherapy | 57%, / | / | 72%, / |
Gentile, 2017 [29] | Nasopharynx ACC involving the skull base | 14 | Proton beam therapy | / | / | 59%, / |
Saitoh, 2017 [39] | Inoperable adenocarcinomas | 47 | Carbon-ion radiotherapy | 79.3%, / | / | 43.4%, / |
Jensen, 2015 [40] | Inoperable or subtotally resected ACC | 58 | Intensity-modulated radiotherapy (IMRT) and carbon-ion therapy | 59.6%, / | 48.4%, / | 76.5%, / |
Jensen, 2015 [30] | 37 | Photon therapy | 39.9%, / | 27%, / | 58.7%, / | |
Inoperable malignant salivary gland tumors | 16 | Carbon-ion therapy followed by IMRT | (3-year) 75, / | (3-year) 49.2%, / | (3-year) 74.5%, / | |
Takagi, 2014 [31] | Inoperable ACC | 56 | Proton therapy or carbon-ion therapy alone | 66%, / | 34%, / | 51%, / |